leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 21:24:20 - browse：88

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Americans' trust in science, scientist continues decline: Report

WSS

Chemotherapy shortages won’t get better under Biden’s latest plan

Pharma patents targeted by Biden in move to slash drug prices

What causes an itch? Researchers may have solved the mystery

Spinal cord stimulation reduces pain in amputees, study finds

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Pregnancy discrimination could be enabled by AI

hotspot

leisure time

knowledge

Cancer drug shortages should be causing more outrage

Patients' immediate access to test results puts radiologists in a bind

At least 13 dead in Texas as scorching temps continue

Woodcock on FDA’s accelerated approval and her next chapter

Hepatitis C has a cure — but many Americans still lack access to it

The woman behind the Dana Farber

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The real point of Kenneth Smith’s execution by nitrogen gas

Bright Health sells Medicare Advantage business to Molina

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Wikipedia

Even great ERs can’t make up for American health disparities

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Some dementia cases could be undiagnosed liver disease

What PEPFAR has meant on the ground in Ukraine

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Time to name cancers by genetics, not organ of origin, expert says

entertainment

knowledge

focus

leisure time